Equity research and Presentations
Here you will find all the equity research made by analysts who follow Active Biotech. You will also find presentations of the company both as video and pdf.
Equity research
- Aktiespararna: Active Biotech: Nytt kapital behövs (in Swedish)2024-09-19
- Aktiespararna: Active Biotech: “Planering för kommande studier” (in Swedish)2024-05-14
- Redeye: Active Biotech Q4 2023: Three Externally Funded Trials in 20242024-02-19
- Aktiespararna: Analysis Active Biotech: “Nytt fokus i kommande studier” (in Swedish)2024-02-19
- Aktiespararna: Analysis Active Biotech: “Fokus på nytt område” (in Swedish)2023-11-15
- Aktiespararna: Analysis Active Biotech: “Översyn av portföljen” (in Swedish)2023-05-09
- Redeye: Active Biotech Q1 2023: New Results from naptumomab2023-05-04
- Redeye: Active Biotech: Interim Phase Ib Results from NeoTX2023-04-17
- Aktiespararna: Analysis Active Biotech: “Vägskäl närmar sig” (in Swedish)2023-02-21
- Redeye: Active Biotech Q4 2022: Laquinimod Ready for Phase II 2023-02-092023-02-09
- Redeye: Active Biotech: Positive Phase I Results2023-01-30
- Aktiespararna: Analysis Active Biotech: “NAP-projekt avancerar” (in Swedish)2022-11-09
- Redeye: Active Biotech Q3 2022: Approaching important milestones2022-11-07
- Aktiespararna: Analysis Active Biotech: “Ögonstudie utökas” (in Swedish)2022-08-11
- Redeye: Active Biotech Q1’22: Our comments and updated valuation2022-04-29
- Aktiespararna: Analysis Active Biotech: “Nya steg mot avtal” (in Swedish)2022-04-27
- Aktiespararna: Analysis Active Biotech: “Breddad klinisk portfölj” (in Swedish)2022-02-18
- Redeye: Advancing Three Active Projects2022-02-18
- Aktiespararna: Analysis Active Biotech: “Effektsignal i fas 1” (in Swedish)2021-11-15
- Sverige Aktiesparares Riksförbund: Ny plan för ögonstudie (in Swedish)2021-08-12
- Sverige Aktiesparares Riksförbund: Siktet inställt på nya mål (in Swedish)2021-04-29
- Redeye: Derisked and Repurposed2020-12-14
Presentations
- Infocus interview with CEO Helen Tuvesson at Redeye Growth Day 2023, May 302024-06-03
- Interview with Prof. Dr. Axel Glasmacher, Independent Board Member at Active Biotech2024-05-13
- CEO Helén Tuvesson presents at Investing in Oncology Forum – April 10, 20242024-04-10
- Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis, audiocast summary2023-12-01
- financialhearings.com – audiocast, the clinical plan and positioning of tasquinimod in myelofibrosis2023-12-01
- Active Biotech: CEO Helén Tuvesson presents at Redeye Life Science Day 2023 – 23 November2023-11-27
- Redeye video interview with CEO Helén Tuvesson (in Swedish)2023-11-16
- Active Biotech presentation at Aktiespararnas “Aktiedag Lund”, October 9, 2023 (in Swedish)2023-10-10
- Infocus interview with CEO Helen Tuvesson at Redeye Growth Day 2023, June 12023-06-07
- CEO Helene Tuvesson presents at Redeye Fight Cancer 20232023-01-23
- Infocus interview with CEO Helén Tuvesson at Redeye Life Science Day 2022 (in Swedish)2022-11-29
- Active Biotech presentation at Aktiespararnas “Aktiedagen Lund”, September 26, 2022 (in Swedish)2022-09-27
- Redeye interview with CEO Helén Tuvesson (in Swedish)2022-08-22
- In Focus interview with Helén Tuvesson CEO at Redeye Growth Day 20222022-06-10
- Active Biotechs presentation at Aktiespararnas “Aktiedagen Lund” January 31, 20222022-01-31
- Active Biotech presentation at Aktiespararnas “Aktiedag Lund” (in Swedish)2021-09-28
- CEO Helen Tuvesson presents at Redeye Growth Day 2021 (Swedish)2021-06-07
- Active Biotech’s presentation at ABGSC Life Science Summit 25 maj 20212021-05-28
- Active Biotech’s presentation at “Aktiedagen” May 4, 2021 (Swedish shareholders’ association, in Swedish)2021-05-04
- Active Biotech’s presentation at Solebury Trout European Biotech Investor Days 20212021-05-02
- “Hur bygger man ett lönsamt Life Science-bolag? – Aktiedagen” January 27, 2021 (in Swedish)2021-01-27
- CEO Helen Tuvesson presents at Redeye Life Science Day 2020 (in Swedish)2020-12-01
- Laquinimod – Treatment of Inflammatory Eye Disorders2020-11-24
- Laquinimod – Treatment of Inflammatory Eye Disorders (PDF)2020-11-24
- Tasquinimod – Treatment of Multiple Myeloma2020-11-24
- Tasquinimod – Treatment of Multiple Myeloma (PDF)2020-11-24
- An Introduction to Multiple Myeloma2020-11-24
- An Introduction to Multiple Myeloma (PDF)2020-11-24
- A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma2020-11-24
- A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma (PDF)2020-11-24
- Naptumomab – Next generation immunotherapy capable of targeting cold tumors2020-11-24
- Naptumomab – Next generation immunotherapy capable of targeting cold tumors (PDF)2020-11-24
- Capital Markets Day 20202020-11-24